Loading...
We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord
- Ticker
- SNY
- Price
- 47.86
- Stock movement up
- +0.08 (0.16%)
- Company name
- Sanofi ADR
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Drug Manufacturers - General
- Market cap
- 123.44B
- Ent value
- -
- Price/Sales
- 2.07
- Price/Book
- -
- Div yield
- 4.37%
- Div growth
- 3.22%
- Growth years
- 2
- FCF payout
- 118.59%
- Trailing P/E
- 17.56
- Forward P/E
- 9.88
- PEG
- -
- EPS growth
- 20.01%
- 1 year return
- -7.17%
- 3 year return
- 4.14%
- 5 year return
- 0.11%
- 10 year return
- -0.51%
Last updated: 2025-09-15
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
DIVIDENDS
Dividend yield - 5y
Loading...
Dividend yield data
| Dividend per share | 2.21 |
| Dividend yield | 4.37% |
| Payout frequency | Annual |
| Maximum yield | 4.85% |
| Average yield | 3.79% |
| Minimum yield | 3.04% |
| Discount to avg yield | 13.26% |
| Upside potential | 15.28% |
| Yield as % of max yield | 90.18% |
Yield distribution (inverse percentile) - 5y
Loading...
Yield distribution data
| Dividend yield | 4.37% |
| Current yield distribution | 7.22% |
| Yield at 100% (Min) | 3.04% |
| Yield at 90% | 3.36% |
| Yield at 80% | 3.47% |
| Yield at 50% (Median) | 3.74% |
| Yield at 20% | 4.13% |
| Yield at 10% | 4.28% |
| Yield at 0% (Max) | 4.85% |
Dividend per share
Loading...
Dividend per share data
| Years of growth | 2 years |
| CCC status | - |
| Dividend per share | 2.21 |
| Payout frequency | Annual |
| Ex-div date | 9 May 2025 |
| EPS (TTM) | 2.81 |
| EPS (1y forward) | 5.05 |
| EPS growth (5y) | 20.01% |
| EPS growth (5y forward) | - |
Dividend growth
Loading...
Please create a free account or log in to access this chart
Dividend growth data
| SNY | S&P500 | |
| DGR MR | 8.58% | -13.74% |
| DGR TTM | 8.58% | 6.60% |
| DGR 3 years | 2.25% | 5.24% |
| DGR 5 years | 3.22% | 5.40% |
| DGR 10 years | 0.65% | 7.07% |
| DGR 15 years | 2.44% | 6.12% |
| Time since last change announced | 185 days |
| EPS growth (5y) | 20.01% |
| EPS growth (5y forward) | - |
Payout ratio
Loading...
Please create a free account or log in to access this chart
Payout ratio data
| EPS coverage | FCF coverage | |
| TTM | 68.87% | 118.59% |
| Average | 58.62% | 50.94% |
| Forward | 43.18% | - |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | 17.56 |
| Price to OCF | 15.21 |
| Price to FCF | 30.23 |
| Price to EBITDA | 11.48 |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 2.07 |
| Price to Book | - |
| EV to Sales | - |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 2.44B |
| EPS (TTM) | 2.81 |
| FCF per share (TTM) | 1.63 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 59.54B |
| Gross profit (TTM) | 36.10B |
| Operating income (TTM) | 11.45B |
| Net income (TTM) | 7.03B |
| EPS (TTM) | 2.81 |
| EPS (1y forward) | 5.05 |
Margins
Loading...
Margins data
| Gross margin (TTM) | 60.64% |
| Operating margin (TTM) | 19.24% |
| Profit margin (TTM) | 11.81% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 0.00 |
| Net receivables | 0.00 |
| Total current assets | 0.00 |
| Goodwill | 0.00 |
| Intangible assets | 0.00 |
| Property, plant and equipment | 0.00 |
| Total assets | 0.00 |
| Accounts payable | 0.00 |
| Short/Current long term debt | 0.00 |
| Total current liabilities | 0.00 |
| Total liabilities | 0.00 |
| Shareholder's equity | 0.00 |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | 8.12B |
| Capital expenditures (TTM) | 4.04B |
| Free cash flow (TTM) | 4.08B |
| Dividends paid (TTM) | 4.84B |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | - |
| Return on Assets | - |
| Return on Invested Capital | - |
| Cash Return on Invested Capital | - |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 50.61 |
| Daily high | 51.00 |
| Daily low | 50.53 |
| Daily Volume | 1.49M |
| All-time high | 59.42 |
| 1y analyst estimate | 62.17 |
| Beta | 0.41 |
| EPS (TTM) | 2.81 |
| Dividend per share | 2.21 |
| Ex-div date | 9 May 2025 |
| Next earnings date | 24 Oct 2025 |
Downside potential
Loading...
Downside potential data
| SNY | S&P500 | |
| Current price drop from All-time high | -14.83% | -1.46% |
| Highest price drop | -49.96% | -56.47% |
| Date of highest drop | 6 Mar 2009 | 9 Mar 2009 |
| Avg drop from high | -17.30% | -10.99% |
| Avg time to new high | 71 days | 12 days |
| Max time to new high | 1902 days | 1805 days |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
COMPANY DETAILS
Marketcap
123.44B
Marketcap category
Large-cap
Description
Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. The company provides immunology and inflammation, rare diseases, neurology, oncology, and other medicines and vaccines. It also offers poliomyelitis, pertussis, and haemophilus influenzae type b (Hib) pediatric vaccines; respiratory syncytial virus protection and hexavalent combination vaccines protecting against diphtheria, tetanus, pertussis, polio, Hib, and hepatitis B; influenza, booster, meningitis, and travel and endemic vaccines, which includes hepatitis A, typhoid, yellow fever, and rabies vaccines. In addition, the company has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301, a treatment for alpha-synucleinopathies; Innate Pharma SA for a natural killer cell engager program targeting B7-H3; and Blackstone Life Sciences to develop pivotal studies and clinical development program. Further, it has a collaboration agreement with IGM Biosciences, Inc. to develop, manufacture, and commercialize IgM antibody; Kymera Therapeutics, Inc. to develop and commercialize protein degrader therapies targeting IRAK4 in patients with immune-inflammatory diseases; Nurix Therapeutics, Inc. to develop novel targeted protein degradation therapies; Denali Therapeutics Inc. to treat a range of systemic inflammatory diseases, such as ulcerative colitis; and Adagene Inc. for the discovery and development of antibody-based therapies. Additionally, it has a collaboration with Scribe Therapeutics Inc. to develop genome editing technologies; and co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab, as well as an strategic alliance with the Department of Health " Abu Dhabi for the development of global vaccines. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was incor
Employees
82878
Website
Investor relations
-
SEC filings
CEO
Paul Hudson
Country
USA
City
Paris
Stock type
American depositary share
CCC status
-
Dividend Frequency
Annual
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
iO Charts is a Seeking Alpha partnerNext page